335 related articles for article (PubMed ID: 30738463)
1. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
3. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
Chen YX; Li Y; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
[TBL] [Abstract][Full Text] [Related]
4. The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.
Şahin E; Yönal-Hindilerden İ; Hindilerden F; Aday A; Nalçacı M
Turk J Med Sci; 2022 Feb; 52(1):150-165. PubMed ID: 34482679
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
7. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
[TBL] [Abstract][Full Text] [Related]
8. The Combination of
Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X
Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Analysis of Gene Mutation and Vascular Events in Patients with BCR/ABL Negative Myeloproliferative Neoplasms].
Hu BD; Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):813-818. PubMed ID: 35680810
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms.
Liang F; Liang X; Pan L; Jin Q; Deng J; Hong M; Wei W; Hao Z; Ren H; Wang H; Chen X
Clin Exp Med; 2024 May; 24(1):106. PubMed ID: 38771542
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
12. [JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation].
Sun CC; Li Y; Tian WJ; Chen YJ; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1022-6. PubMed ID: 25130821
[TBL] [Abstract][Full Text] [Related]
13. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
15. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
16. [Variation of STAT3 Gene in Myleproliferative Neoplasms and Its Significance].
Tan M; Luo X; Su Q; Huang CS; Yang YH; Rong Y; Zhu P; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1430-1436. PubMed ID: 30295263
[TBL] [Abstract][Full Text] [Related]
17. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
[TBL] [Abstract][Full Text] [Related]
18. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
19. Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.
Rashid M; Ahmed RZ; Ahmed S; Nadeem M; Ahmed N; Shamsi TS
Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):112-116. PubMed ID: 27408370
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
